SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
Chemokines and their receptors in esophageal cancer--the systematic review and future perspectives.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Comparison of the clinical usefulness of CXCL-8 and conventional clinical tumor markers for gastric cancer diagnosis.Clinics (Sao Paulo, Brazil) · 2026Article
- Effects of FAP+ fibroblasts on cell proliferation migration and immunoregulation of esophageal squamous carcinoma cells through the CXCL12/CXCR4 axis.Molecular and cellular biochemistry · 2025Article
- Level and clinical significance of serum CXC chemokine ligand 13 in patients with hepatocellular carcinoma.Translational cancer research · 2025Article
- Exploring Potential Biomarkers in Oesophageal Cancer: A Comprehensive Analysis.International journal of molecular sciences · 2024Review
- The Comprehensive Analysis of Specific Proteins as Novel Biomarkers Involved in the Diagnosis and Progression of Gastric Cancer.International journal of molecular sciences · 2023Review
- Identification and characterization of FGFR2Journal of experimental & clinical cancer research : CR · 2022Article
- Article
- Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?Frontiers in endocrinology · 2021Review
- The Role of Chemokines in the Development of Gastric Cancer - Diagnostic and Therapeutic Implications.International journal of molecular sciences · 2020Review
- Correlation between CXCR4, CXCR5 and CCR7 expression and survival outcomes in patients with clinical T1N0M0 non-small cell lung cancer.Thoracic cancer · 2020Article
- Review
- Anti-CXCR4 Single-Chain Variable Fragment Antibodies Have Anti-Tumor Activity.Frontiers in oncology · 2020Article
- Function and therapeutic advances of chemokine and its receptor in nonalcoholic fatty liver disease.Therapeutic advances in gastroenterology · 2018Review
- Expression of CCR6 in esophageal squamous cell carcinoma and its effects on epithelial-to-mesenchymal transition.Oncotarget · 2017Article
- CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma.Cell death & disease · 2017Article
- The Serum Concentrations of Chemokine CXCL12 and Its Specific Receptor CXCR4 in Patients with Esophageal Cancer.Disease markers · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer (EC) is an aggressive malignant solid tumor with rapid progression and unfavorable prognosis. The 5-year survival rate for EC patients was estimated to be less than 10 %. Therefore, there is an urgent need to improve diagnostic tool and effective treatment therapies for EC patients. In our paper, the general structure and function of chemokines and their receptors as well as their role in cancer progression were shortly presented. Moreover, the aim of our paper was to summarize and refer the current findings concerning the role of selected chemokines and their receptors as candidates for tumor markers of EC. Some clinical investigations have proved the involvement of these proteins in proliferation, migration, invasiveness and metastasis of tumor cells. Increasing evidence from previous studies suggested that C-X-C motif chemokine 12 (CXCL12), also known as stromal cell-derived factor 1 (SDF-1) and its receptor CXCR4 may provide novel diagnostic and prognostic strategies to reduce the burden of EC. Moreover, therapy targeting the CXCL12/CXCR4 axis may open a new direction for treatment of EC patients. However, given their nonspecific nature, the diagnostic value of chemokines and their receptors may be limited. Therefore, future larger investigations, especially in the blood of EC patients, still need to be continued to further clarify the significance of these proteins as potential candidates for tumor markers in diagnosis and prognosis of EC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.